ASX dividend shares can be some of the best ways to unlock a good level of passive income. I want to highlight two businesses that have dividend yields above 6%.

I think some dividend yields can be too high if they’re not going to be sustainable payouts for the long-term. I don’t want to invest in things where the dividend payout is likely to decline in the coming years.

Of course, dividends are not guaranteed. But, some businesses are more likely to grow their payouts than others. Below are two I’m excited by.

Dexus Industria REIT (ASX: DXI)

This business is a real estate investment trust (REIT) that invests in industrial property across Australia. The industrial property sector has a low vacancy rate, which is a useful tailwind for rental growth, along with demand growth in areas like e-commerce adoption and data centres.

The ASX dividend share’s FY26 payout comes to 16.6 cents per security, representing a distribution payout ratio of 95.4%. I think it’s useful to see when a business is retaining some of its profit to invest in future opportunities.

The projected payout comes to a dividend yield of 6.8%. This business looks like a bargain to me because it’s trading at a 28% discount to the net tangible assets (NTA) of $3.39 as of 31 December 2025.

The fund manager of the REIT, Jason Weate, said with the HY26 result:

While the industrial sector has continued to normalise, underlying supply-demand fundamentals are solid. Vacancy remains low across core industrial markets, with high land and construction costs putting pressure on pipelines. In the medium to long term, the sector will continue to be supported by a growing population and limited available supply.

In my view, this bodes well for the ASX dividend share’s future payouts, particularly if the business can continue its solid mid-to-high single digit rental income growth.

MFF Capital Investments Ltd (ASX: MFF)

The other ASX share I want to highlight is this listed investment company (LIC), which aims to invest in high-quality international businesses with competitive advantages that enable them to grow earnings over the long term.

When a LIC generates strong investment returns over time, they can deliver pleasing and rising dividends for investors. MFF is invested in several of the best, strongest companies that enable the MFF portfolio as a whole to do well.

MFF has increased its regular annual dividend per share each year since FY18, so it has already given investors several years of consecutive dividend growth and it wants to continue that track record.

The business has increased its annual dividend per share by 4 cents in the last couple of financial years and I expect this trend to continue in FY27. That means its potential FY27 could be a grossed-up dividend yield of 6.9%, including franking credits, at the time of writing.

The post 2 ASX dividend shares with yields above 6% appeared first on The Motley Fool Australia.

More reading

• How much superannuation is needed to target a $100,000 annual passive income?
• Forget CBA shares! I’d rather buy these ASX dividend shares
• How to invest $5,000 for passive income in superannuation?
• How should I invest my money in FY27?
• How much is needed in superannuation to target a $70,000 annual passive income?

Motley Fool contributor Tristan Harrison has positions in Mff Capital Investments. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has positions in and has recommended Mff Capital Investments. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

If you are hunting for ways to gain exposure to copper and gold outside the giants of BHP Group Ltd (ASX: BHP) and Newmont Corporation (ASX: NEM), then it could be worth considering the ASX stock in this article.

This is especially the case given how Bell Potter believes its shares could rise by over 200% between now and this time next year.

Which ASX copper and gold stock?

The stock that has caught the eye of Bell Potter is LinQ Minerals Ltd (ASX: LNQ).

It is a Perth based gold-copper exploration and development company whose primary asset is the Gilmore Gold-Copper Project. 

Bell Potter highlights that it hosts the full suite of Macquarie Arc intrusive related copper and gold systems and is prospective for a range of economic deposits including analogues to the nearby Northparkes, Cadia, and Cowal systems.

The broker was pleased with the ASX stock’s recent drilling results. It said:

These are strong first pass results from a maiden drill program that has delivered a 3 from 3 strike rate so far. The copper equivalent grades (and constituent gold and copper grades) are competitive with the Resource grades of large-scale copper-gold mines operating in Australia (Carrapateena, Northparkes and Cadia) and development projects such as Evolution Mining’s (EVN, Buy, TP $16.60/sh) Marsden. 

The testing of Monza is at an early stage and results from a further 5 holes from the maiden program are anticipated in the coming weeks. Further strong results could materially upgrade the prospectivity at Monza, see it prioritised by LNQ and gain recognition in the market.

Speculative buy with major upside potential

According to the note, in response to the drilling results, the broker has retained its speculative buy rating and 90 cents price target on the ASX copper and gold stock.

Based on its current share price of 28 cents, this implies potential upside of 220% for investors over the next 12 months.

To put that into context, a $2,000 investment would be worth $6,400 by this time next year if Bell Potter is on the money with its recommendation.

Commenting on its investment thesis, the broker said:

Our valuation is based on a blended EV per Resource ounce multiple and a risk adjusted notional mining scenario, both developed under conservative assumptions. We see the foundations of a competitive development project that is undervalued by the market. Current and planned drilling programs have the potential to highlight this and catalyse a re-rating. We retain our Speculative Buy recommendation.

The post Which ASX copper and gold stock could rocket 200%? appeared first on The Motley Fool Australia.

More reading

• 5 things to watch on the ASX 200 on Wednesday
• Up almost 50%, is it too late to buy BHP shares?
• What did the market look like 10 years ago? Here’s what’s changed for the ASX 200
• 5 things to watch on the ASX 200 on Tuesday
• How much superannuation do you need to earn $5,000 a month in passive income?

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended BHP Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Telix Pharmaceuticals Ltd (ASX: TLX) shares closed 1.3% lower on Tuesday afternoon, at $15.78 a piece.

The decline means the shares have now fallen just over 9% over the past week, sparking concerns that the rebound is now over for Telix shares.

The biopharmaceutical stock tumbled to a multi-year low of $8.63 in mid-February, before recovering over 100% in early July.

The shares are now up around 39% for the year-to-date.

But they’re still roughly 33% lower than trading levels seen 12 months ago, and 48% lower than an all-time high recorded in early 2025.

What caused the rebound?

Telix shares turned a corner in February this year after a series of good-news announcements out of the biotech company. 

In late February, the company confirmed that it had filed for a key regulatory approval in Europe. 

Later in March, Telix posted several announcements about its growth and development plans. 

In early April, Telix announced that the FDA had accepted its NDA for TLX101-Px (Pixclara®) and also announced a major collaboration with US-based biotech company Regeneron Pharmaceuticals. 

It also announced a 56% increase in revenue and issued FY26 guidance in the range of US$950 million to US$970 million.

Then in early July, the company confirmed it has reached an agreement with the FDA to move ahead with the next part of its ProstACT Global Phase 3 study in the US, developed to target prostate cancer.

Why have Telix shares now started tumbling again?

It’s not clear why Telix shares have been tumbling over the past week. There has been no price-sensitive news out of the company to explain the latest sell off. 

It’s most likely a combination of investors taking gains off the table after a strong rally, and a shift in sentiment for ASX healthcare shares overall.

Reignition of conflict in the Middle East has caused a fresh wave of uncertainty across markets, with investors again rotating into more defensive sectors.

Is there any upside left for Telix shares?

According to the experts, there should be a lot more to come from Telix shares over the next 12 months.

TradingView data shows that 15 out of 16 analysts have a buy or strong buy rating on the shares. One more has a hold rating. They all agree we’ll see some upside ahead too.

The average $25.01 target price implies a potential 59% upside at the time of writing. But the more bullish of the bunch forecast the shares to rocket another 101% to $31.65 over the next 12 months.

Morgans has a $24.33 price target on the healthcare stock and said that industry consolidation could spark more interest in Telix shares.

The broker said that recent news flow on its convertible note refinancing, solid sales figures, and collaboration with Regeneron suggests there is plenty happening at Telix. 

There are also several potential milestones ahead for the company this year, including FDA clearance for its Zircalix kidney cancer imaging production and Pixclara for brain cancer imaging.

The post Down 9%: Is the rebound over for Telix shares? appeared first on The Motley Fool Australia.

More reading

• These are the 10 most shorted ASX shares
• These are the 10 most shorted ASX shares
• Here are the top 10 ASX 200 shares today
• Healthcare shares lead the ASX 200 again as sector rotation gathers pace
• Up 55% in 2026! Why this ASX healthcare stock is climbing again

Motley Fool contributor Samantha Menzies has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Telix Pharmaceuticals. The Motley Fool Australia has recommended Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.